Snail2, known in the literature as SNAI2 or by its older name Slug, belongs to the Snail superfamily of C2H2 zinc-finger transcription factors. These proteins bind DNA through characteristic finger-like zinc-coordinated loops and act as molecular switches, repressing or activating entire gene programs. Within this family, Snail2 has earned a reputation as a master regulator of epithelial-mesenchymal transition, the process by which tightly packed epithelial cells loosen their junctions, remodel their cytoskeletons and acquire the motile behavior of mesenchymal cells. What distinguishes Snail2 from its relatives, the review argues, is that it does not typically drive the complete version of this transition. Rather, it promotes a partial EMT, a hybrid state in which cells retain epithelial traits such as cell-cell adhesion while simultaneously gaining mesenchymal motility.

That hybrid state is far from a biological curiosity. In tumors, cells caught between epithelial and mesenchymal identities appear to be the most effective colonizers, capable of detaching, traveling through circulation and then re-establishing themselves at distant sites. Because partial EMT is reversible, cells that complete the journey can revert to a proliferative epithelial phenotype and seed new lesions. The review positions Snail2 as a distinctive driver of this plasticity, contrasting it with other EMT transcription factors that push cells all the way to a fully mesenchymal fate. Understanding precisely how Snail2 calibrates this in-between state, the authors note, remains one of the field’s most pressing unanswered questions.

The regulatory machinery surrounding Snail2 is correspondingly elaborate. The review describes a multi-layered network that controls the protein at every stage of its life cycle. At the transcriptional level, numerous signaling pathways converge on the SNAI2 promoter to determine how much messenger RNA is produced. Post-transcriptional mechanisms, particularly microRNAs and RNA-binding proteins, then determine the stability and translation efficiency of that transcript. Translational control adds a further gate, and post-translational modifications, including phosphorylation, ubiquitination and other chemical tags, govern the stability, localization and activity of the protein itself. This layered architecture means that Snail2 activity can be tuned finely and rapidly, which is exactly what a system requiring reversible cell-state transitions demands.

In normal development, this tunability is put to spectacular use. The review devotes substantial attention to the neural crest, a transient embryonic cell population that arises at the border of the neural plate and gives rise to an astonishing range of tissues, from craniofacial bone and cartilage to neurons of the peripheral nervous system and pigment cells. Snail2 is critical for neural crest formation and migration, endowing these cells with the motility they need to travel long distances across the embryo. Without properly regulated Snail2, neural crest cells fail to delaminate and migrate correctly, with consequences that echo through craniofacial and nervous system development.

The developmental portfolio of Snail2 extends well beyond the neural crest. The review catalogs its involvement in gland development, where branching epithelial structures depend on controlled cell rearrangements; in vascular development, where endothelial cells must remodel into functional networks; and in cardiac valve development, where an EMT-like process generates the cellular cushion tissue of the heart. Snail2 also participates in chondrogenesis and skeletal development, guiding cartilage formation and bone patterning. In each of these contexts, the same underlying logic applies: Snail2 temporarily loosens epithelial constraints or activates migratory programs, then steps back as cells settle into their final differentiated identities. Development, in this view, is a choreography of controlled plasticity, and Snail2 is one of its principal choreographers.

In disease, that same choreography is co-opted to destructive ends. The review details how Snail2 drives cancer progression through epigenetic reprogramming, recruiting repressive complexes to silence epithelial genes such as those encoding cell adhesion molecules, while activating mesenchymal and stemness-associated programs. The result is a tumor cell equipped for invasion, metastasis, self-renewal and resistance to chemotherapy. Chemoresistance is a particularly consequential outcome, because cells in a partial EMT state can survive cytotoxic insults that kill their more differentiated neighbors, then repopulate the tumor once treatment ends. Snail2’s role in maintaining this resilient subpopulation makes it an attractive target for therapies aimed not just at shrinking tumors but at eliminating the cells responsible for relapse.

The pathological reach of Snail2 is not confined to cancer. The review links it to cardiovascular, respiratory, renal and gynecological disorders, all unified by a common mechanism: EMT-mediated tissue remodeling and chronic inflammation. In fibrotic diseases of the lung and kidney, for example, epithelial cells that undergo partial EMT contribute to the accumulation of matrix-producing cells that progressively stiffen and destroy organ function. In vascular disease, endothelial cells that lose their identity through similar transitions contribute to plaque instability and dysfunction. In gynecological tissues, aberrant EMT-like programs underlie pathological remodeling processes. Across all of these systems, Snail2 sits at a regulatory node where inflammatory signals and tissue injury converge on cell-state change.

Despite the breadth of what is known, the review is candid about the gaps. The molecular determinants that specify partial rather than complete EMT remain poorly defined, as do the reasons why Snail2 performs different functions in different cellular contexts. Translational control of Snail2, the mechanisms that determine how efficiently its messenger RNA becomes protein, is another underexplored layer. Perhaps most intriguingly, the authors highlight Snail2’s emerging role in shaping the tumor immune microenvironment, suggesting that the transcription factor may influence not only cancer cells themselves but also how immune cells perceive and respond to them. Resolving these questions, the review argues, will require integrating approaches spanning chromatin biology, single-cell analysis and immunology.

The therapeutic implications are considerable but cautionary. Directly inhibiting a transcription factor has historically been difficult, and Snail2’s essential roles in development and tissue repair mean that systemic suppression carries risks. The more realistic near-term strategy, the review suggests, is to target the regulatory network around Snail2, the kinases, ubiquitin ligases, microRNAs and chromatin modifiers that keep it in check, or to exploit the vulnerabilities of the hybrid epithelial-mesenchymal state it maintains. As metastasis remains the leading cause of cancer death, a deeper mechanistic grasp of the protein that governs cellular plasticity could reshape how clinicians think about preventing spread rather than merely treating established tumors. For a factor once studied mainly in embryology textbooks, Snail2 has become a focal point where developmental biology and cancer medicine converge.

Subject of Research: The roles and regulatory mechanisms of the transcription factor Snail2 in epithelial-mesenchymal transition, development and disease

Article Title: Snail2: roles and regulatory mechanisms in development and disease

Article References: Chen, Y., He, Z., Jiao, Y., Hao, H., Cui, Z., Zhao, K., Cong, X., & Hu, Y. (2026). Snail2: roles and regulatory mechanisms in development and disease. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03351-0

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03351-0

Keywords: Snail2, SNAI2, epithelial-mesenchymal transition, partial EMT, transcription factor, neural crest, metastasis, cancer, chemoresistance, cell plasticity, epigenetic reprogramming, tumor microenvironment